Treatment Access Solution

A collaboration with Celgene Thailand

Revlimid® (lenalidomide)

The Max Foundation partners with Celgene Thailand to increase access to Revlimid® (lenalidomide) through the IMiDs Patient Assistance Program (I-PAP) for multiple myeloma patients in Thailand who meet the medical criteria and program guidelines.

Contact us for more information about how to access Revlimid® for multiple myeloma patients in Thailand.

Return to Treatment Access Solutions